<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655225</url>
  </required_header>
  <id_info>
    <org_study_id>13517</org_study_id>
    <secondary_id>I6A-MC-CBBA</secondary_id>
    <nct_id>NCT01655225</nct_id>
  </id_info>
  <brief_title>A Study of LY3023414 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find a recommended dose level and schedule of dosing
      LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The
      study will also explore the changes to various markers in blood cells and potentially tumor
      cells. Finally, the study will help document any antitumor activity this drug may have.

      In Part A of this study, participants with advanced/metastatic cancer (including lymphoma)
      will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in
      different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>Baseline to disease progression or participant discontinuation (estimated 9 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax)</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of maximal concentration</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with tumor response</measure>
    <time_frame>Baseline to disease progression or participant discontinuation (estimated 9 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential of LY3023414 to inhibit CYP3A4-mediated metabolism</measure>
    <time_frame>Baseline through Cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: LY3023414 Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A2: LY3023414 Twice Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B1 : LY3023414 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B2: LY3023414 + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B3: LY3023414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B4: LY3023414 + pemetrexed/cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B5: LY3023414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B6: LY3023414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B7: LY3023414 + Abemaciclib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Administered orally. Dose of 20 to 600 mg, as determined in Part A.</description>
    <arm_group_label>Part A: LY3023414 Once Daily</arm_group_label>
    <arm_group_label>Part A2: LY3023414 Twice Daily</arm_group_label>
    <arm_group_label>Part B1 : LY3023414 + Midazolam</arm_group_label>
    <arm_group_label>Part B2: LY3023414 + Fulvestrant</arm_group_label>
    <arm_group_label>Part B3: LY3023414</arm_group_label>
    <arm_group_label>Part B4: LY3023414 + pemetrexed/cisplatin</arm_group_label>
    <arm_group_label>Part B5: LY3023414</arm_group_label>
    <arm_group_label>Part B6: LY3023414</arm_group_label>
    <arm_group_label>Part B7: LY3023414 + Abemaciclib + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.</description>
    <arm_group_label>Part B1 : LY3023414 + Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.</description>
    <arm_group_label>Part B2: LY3023414 + Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 administered IV once on Day 1 every 21 days</description>
    <arm_group_label>Part B4: LY3023414 + pemetrexed/cisplatin</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 administered IV once on Day 1 every 21 days</description>
    <arm_group_label>Part B4: LY3023414 + pemetrexed/cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B7: LY3023414 + Abemaciclib + Letrozole</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B7: LY3023414 + Abemaciclib + Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parts A, A2 &amp; B1: Participants must have pathological evidence of a diagnosis of
             advanced and/or metastatic cancer and must be, in the judgment of the investigator, an
             appropriate candidate for experimental therapy

          -  Part B2: Participants must have advanced, recurrent, or metastatic breast cancer that
             is refractory to aromatase inhibitors (AI) with either disease recurrence or disease
             progression; must be hormone receptor positive (HR+) and human epidermal growth factor
             receptor 2 (HER2)-negative; must be of postmenopausal status or beginning ovarian
             suppression with a luteinizing hormone-releasing hormone (LHRH) agonist

          -  Part B3 only: Participants must have malignant pleural or peritoneal mesothelioma

          -  Part B4 only: Participants must have malignant pleural or peritoneal mesothelioma and
             appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic
             chemotherapy

          -  Part B5 only: Participants must have histologically confirmed diagnosis of B-cell
             iNHL, with histological subtype; prior treatment with ≥2 prior chemotherapy- or
             immunotherapy-based regimens for iNHL

          -  Part B6 only: Participants must have squamous NSCLC; documented evidence of an
             activating molecular aberration of the PI3K/mTOR pathway

          -  Parts B2, B3 &amp; B6 only: Must have adequate tumor tissue sample from archival biopsy
             available, or willingness to undergo a fresh tumor biopsy

          -  Parts B3, B4, B5 &amp; B6: No previous treatment with any PI3K and/or mTOR inhibitor

          -  Part B7: Must have a diagnosis of HR+ and HER2- breast cancer; have locoregionally
             recurrent disease not amenable to resection or radiation therapy with curative intent
             or metastatic disease; no previous treatment or currently receiving 1 of the following
             treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy,
             endocrine therapy, CDK4/6 inhibitor, and PI3K and/or mTOR inhibitor)

          -  Measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in
             Solid Tumors (RECIST Version 1.1), modified RECIST or Revised Response Criteria for
             Malignant Lymphoma

          -  Have adequate organ function, including: Absolute neutrophil count (ANC) at least 1.5
             x 109/Liter (L), platelets at least 100 x 109/L, and hemoglobin at least 8
             grams/deciliter (g/dL); bilirubin no more than 1.5 times upper limits of normal;
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) no more than 2.0
             times upper limits of normal; Serum creatinine no more than 1.5 times upper limits of
             normal or calculated creatinine clearance &gt;45 milliliters/minute (mL/min)

          -  Have a performance status of at least 1 on the Eastern Cooperative Oncology Group
             (ECOG) scale and life expectancy &gt;6 months

          -  Have discontinued all previous cancer therapies (except nonsteroidal aromatase
             inhibitors for participants in Part B2), and any agents that have not received
             regulatory approval for any indication, for at least 21 days or 5 half lives prior to
             study enrollment, whichever is shorter, and recovered from the acute effects of
             therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at
             least 42 days

          -  Are able to swallow capsules

        Exclusion Criteria:

          -  Have serious preexisting medical conditions

          -  Have symptomatic central nervous system (CNS) malignancy (with the exception of
             medulloblastoma) or metastasis (screening not required).

          -  Have known acute or chronic leukemia or current hematologic malignancies (except iNHL
             for patients in Part B5) that, in the judgment of the investigator and sponsor, may
             affect the interpretation of results

          -  Have an active fungal, bacterial, and/or known viral infection

          -  Have a second primary malignancy that in the judgment of the investigator and sponsor
             may affect the interpretation of results (Part B only)

          -  Part B1 only: No concomitant medications that are strong inhibitors or inducers of
             cytochrome P450 3A4 (CYP3A4) or midazolam

          -  Intolerance to any previous treatment with any phosphatidylinositol-3-kinase (PI3K)
             and/or mammalian target of rapamycin (mTOR) inhibitor.

          -  Participants with active alcohol abuse, as determined by the investigator

          -  Have a history of New York Heart Association (NYHA) Class ≥3, unstable angina, or
             myocardial infarction (MI) in 6 months prior to study drug administration

          -  Have QT corrected interval of &gt;450 milliseconds (msec) on screening electrocardiogram
             (ECG)

          -  Have insulin-dependent diabetes mellitus or a history of gestational diabetes
             mellitus.

          -  Part B only: Hypersensitivity to study drugs given in combination with LY3023414
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-325-8252</phone>
    </contact>
    <investigator>
      <last_name>Parvin Peddi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-888-4226</phone>
    </contact>
    <investigator>
      <last_name>Anna Varghese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Oklahoma Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-8777</phone>
    </contact>
    <investigator>
      <last_name>Raid Aljumaily</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-789-7366</phone>
    </contact>
    <investigator>
      <last_name>Evan Alley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO Sarah Cannon Research Inst.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877221248</phone>
    </contact>
    <investigator>
      <last_name>Mirelis Acosta-Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/advanced-cancer/CBBA#?postal=</url>
    <description>Click here for more information about this study: A Study of LY3023414 in Participants With Advanced Cancer</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Advanced Lung Cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

